Advertisement

Why an Upcoming FDA Meeting Is Critical for Biogen Stock

Why an Upcoming FDA Meeting Is Critical for Biogen Stock

Ever since Biogen (NASDAQ: BIIB) revived a phase 3 Alzheimer's program a year ago, investors have been waiting with bated breath for the next steps. The company submitted aducanumab, the investigational Alzheimer's treatment, for regulatory review in July. Now, an advisory committee is set to meet on Nov. 6 to weigh in on whether the U.S. Food and Drug Administration (FDA) should approve the drug candidate.